



Alliance at ASCO 2016

The 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene in Chicago June 3-7, bringing together more than 34,000 oncology professionals from around the world. This year's meeting theme, "Collective Wisdom: the Future of Patient-Centered Care and Research," focuses on the power of combining knowledge - across disciplines, disease sites, and treatment approaches - to evolve and shape the future of patient care and research. The theme encourages the exploration of advances in big data technology that are speeding up collective discovery and revealing new insights faster than ever before.

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance scientists will present more than 15 studies, sharing the latest findings on breast cancer, brain cancer, hematologic cancers, and gastric cancer, along with cancer control research.

[Join the Twitter conversation at #ASCO16](#) and please include **@ALLIANCE_org**

Here's a snapshot of studies that Alliance researchers will be presenting:

Breast Cancer-HER2/ER

[A genome-wide association study \(GWAS\) of progression-free survival \(PFS\) in metastatic breast cancer \(MBC\) patients treated with letrozole \(L\) with or without bevacizumab \(B\) in CALGB 40503](#)

Presenter: **Federico Innocenti**

Study #: 40503

Abstract # 538 | Hall A | Poster Session (Board #26) | Poster

June 5, 2016, 8 am to 11:30 am

Breast Cancer-Triple-Negative/Cytotoxics/Local Therapy

[Accrual of older patients \(pts\) with breast cancer to Alliance systemic therapy trials over time: A151527](#)

Presenter: **Rachel A. Freedman**

Study #: Alliance 151527

Abstract # 1024 | Poster Session (Board #129) | Oral Presentation

June 5, 2016, 8 am to 11:30 am | | Hall A

[Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node \(Alliance\)](#)

Presenter: **Armando E. Giuliano**

Study #: ACOSOG Z0011

Abstract # 1007 | Hall D2 | Oral Presentation

June 4, 2016, 1:15 pm to 4:15 pm

Central Nervous System Tumors

[Validating RNAseq-signatures of vorinostat \(VOR\) sensitivity and resistance in patients with newly diagnosed glioblastoma \(GBM\) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902](#)

Presenter: **S. Keith Anderson**

Study #: NCCTG N0874/ABTC-0902

Abstract # 2029 | Hall A | Poster Session (Board#218) | Poster

June 4, 2016, 1 pm to 4:30 pm

Gastrointestinal (Colorectal) Cancer

[Blood-based biomarkers in patients \(pts\) with metastatic colorectal cancer \(mCRC\) treated with FOLFOX or FOLFIRI plus bevacizumab \(Bev\), cetuximab \(Cetux\), or bev plus Cetux: Results from CALGB 80405 \(Alliance\)](#)

Presenter: **Andrew B. Nixon**

Study #: CALGB 80405

Abstract # 3597 | Poster Session (Board #294) | Poster

June 4, 2016, 8 am to 11:30 am | Hall A

[Association of tumor infiltrating lymphocytes \(TILs\) with molecular subtype and prognosis in stage III colon cancers \(CC\) from a FOLFOX-based adjuvant chemotherapy trial](#)

Presenter: **Frank A. Sinicrope**

Study #: NCCTG N0147

Abstract # 3518 | Poster Discussion Session (Board #215) | Poster

June 4, 2016, 8 am to 11:30 am | Hall A

[Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials](#)

Presenter: **Frank A. Sinicrope**

Study #: NCCTG N0147

Abstract #: 3600 | Poster Discussion Session (Board #297) | Poster

June 4, 2016, 8 am to 11:30 am | Hall A

[Impact of primary \(1°\) tumor location on overall survival \(OS\) and progression-free survival \(PFS\) in patients \(pts\) with metastatic colorectal cancer \(mCRC\): Analysis of CALGB/SWOG 80405 \(Alliance\)](#)

Presenter: **Alan P. Venook**

Study #: CALGB 80405

Abstract # 3504 | Oral Presentation

June 5, 2016, 8 am to 11 am | Hall B1

Gastrointestinal (Noncolorectal) Cancer

[Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma \(HCC\): CALGB 80802 \(Alliance\)](#)

Presenter: **Ghassan K. Abou-Alfa**

Study #: CALGB 80802

Abstract # 4003 | Oral Presentation

June 6, 2016, 8 am to 11 am | Hall B1

Hematologic Malignancies-Plasma Cell Dyscrasia

[Lenalidomide \(LEN\) maintenance \(MNTC\) after high-dose melphalan and autologous stem cell transplant \(ASCT\) in multiple myeloma \(MM\): A meta-analysis \(MA\) of overall survival \(OS\)](#)

Presenter: **Michel Attal**

Study #: CALGB 100104

Abstract # 8001 | Oral Presentation

June 3, 2016, 3 pm to 6 pm | Location: E354b

Patient and Survivor Care

[Identifying risk factors for toxicity in patients \(pts\) with hormone-receptor positive \(HR+\) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 \(Alliance\) correlative study](#)

Presenter: **Daneng Li**

Study #: CALGB 40503

Abstract # 10047 | Poster

June 6, 2016, 1 pm to 4:30 pm | Hall A

[Impact of age and comorbidity on treatment of non-small cell lung cancer \(NSCLC\) recurrence \(AFT-03\)](#)

Presenter: **Melisa L. Wong**

Study #: AFT-03

Abstract # 10037 | Poster Session (Board #25)

June 6, 2016, 1 pm to 4:30 pm | Hall A

Sarcoma

[A phase I/randomized phase II study of MLN0128 vs pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304](#)

Presenter: **William D. Tap**

Study #: Alliance A091304

Abstract # TPS11073 | Poster Session (Board #197b) | Poster

June 6, 2016, 8 am to 11:30 am | Hall A

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2016 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Gastrointestinal (Colorectal) Cancer

[Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable \(MSI\) colon cancers: Findings from CALGB](#)

Presenter: **Christina Sing-Ying Wu**

Abstract # e15148 | Publication Only

Study #: CALGB 89803 / N0147

Health Services Research and Quality of Care

[Detection and treatment of colorectal cancer \(CRC\) recurrence during routine surveillance: A nationwide cohort study](#)

Presenter: **Rebecca A Snyder**

Abstract # e18137 | Publication Only

Study #: AFT-02

[Association between patient perception of oncology clinical trial participation and survival: N0392 \(Alliance\)](#)

Presenter: **Jennifer Le-Rademacher**
Abstract # e18122 | Publication Only
Study #: NCCTG N0392

ALLIANCE MEMBERS ON THE MOVE AT ASCO

Clifford A. Hudis, MD | Named Incoming CEO of ASCO
[Learn more about Dr. Hudis' new role](#) in *The Cancer Letter*.

[The Atlantic's The Search for Answers: Fighting Rare Cancers - Panel](#)

Alliance members - [William D. Tap, MD](#); [Jedd D. Wolchok, MD](#); and [Richard L. Schilsky, MD](#) - will participate in a panel discussion hosted by *The Atlantic* to examine how new strategies in the fight against rare cancer can revolutionize the treatment paradigm; how rare cancer communities are mobilizing at the grassroots level; and how the White House's recently announced Moonshot initiative will impact cancer research. The event will be held in Chicago a day before ASCO begins on June 2. Take a look at the [agenda](#).

Alliance for Clinical Trials in Oncology



Alliance for Clinical Trials in Oncology | Chicago Office | 125 South Wacker Drive, Suite 1600 | Chicago | IL | 60606